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Supplement Table 1.  Feedback from OMERACT participants on the PsAID12 
Discussion points by topic 
Overall process and evidence 
 It was noted that a significant amount of work had gone into appraising the instruments, and that both 
were backed by a substantial body of evidence. 
 A number of participants felt that the instrument could achieve an overall “Green” rating given the 
body of evidence supporting Domain Match, Feasibility and Construct validity, whereas other 
participants felt that discrimination was a critical aspect of an instrument and that an “Amber” rating in 
any of the discrimination sub-categories should result in an overall “Amber” rating. 
  
Content validity  
 It was noted that the PsAID questionnaire captures items that may not be relevant to all patients, and 
concerns around how this might impact the overall score.  There were also some concerns regarding 
the anchors used.   
 Whether patients could conceptualize “due to psoriatic arthritis” is referring to their condition if they 
do not have arthritis manifestations.  Probably not a major concern, as patients voted positively for 
domain match. Whether patients ratings for items like embarrassment/ fatigue/ others can really 
differentiate that it is effect of Psoriatic arthritis rather than other comorbidities (disease attribution) 
 
Feasibility 
 Weighted scores impact feasibility. 
 
Construct validity 
 Potentially different constructs simultaneously assessed by items work/leisure (#4), 
anxiety/fear/uncertainty (#9), embarrassment/shame (#10) 
 Concern these items may not be as sensitive to change with treatment. 
 
Discrimination 
 Some confusion regarding the use of a LOS to assess discrimination, with many people in the 
breakout group believing that this evidence has to come from an RCT.  Some participants felt that 
discrimination in clinical trials was a critical aspect for an instrument, particularly as the objective is to 
find instruments to be used in RCTs, and this was noted to be especially important to Industry.  One 
of 8 breakout groups suggested RCT discrimination should have been white rather than amber 
(15/17). 
 OMERACT TAG has clarified that cohort study longitudinal data can be taken as bronze level 
evidence.  Since RCT information is missing can proceed with amber based on LOS and mandatory 
to address the gaps of knowledge: RCT data.  Research agenda: RCT discrimination and Thresholds 
of meaning. 
 
Suggestions 
 Skin item (#3): change attribution to psoriasis instead of psoriatic arthritis. 
 Inconsistency across anchors for the 12 items when some would prefer consistent anchors.   
 
Other 
 Based on PsAID12 we cannot calculate utilities or economic analysis.  There may be interpretability 
of some questions. 
 Overlap with other domains such as physical function and fatigue was noted. 
Agreement with PsAID12 amber (or better) endorsement as core instrument for PsA RCTs and LOS across 
breakout groups (all considered together): 71/81 (88%) 
 
